Description

// WHAT_IS_CJC-1295 + IPAMORELIN

This 5mg/5mg research blend pairs two of the most co-studied peptides in growth hormone axis research. CJC-1295 without DAC — formally known as GRF(1-29), or Modified GRF — is a synthetic analogue of endogenous Growth Hormone Releasing Hormone (GHRH). The absence of a Drug Affinity Complex (DAC) means a shorter circulating half-life, producing discrete, physiological-pattern GH pulses in laboratory models rather than prolonged supraphysiological elevation. Ipamorelin is a selective pentapeptide GHRP (Growth Hormone Releasing Peptide) and ghrelin receptor (GHSR-1a) agonist. Classified as a third-generation GHRP, it stands out in preclinical data for its GH selectivity — animal models consistently report minimal co-secretion of cortisol or prolactin compared to earlier GHRPs such as GHRP-2 and GHRP-6. The combination is among the most referenced dual-mechanism GH secretagogue stacks in peptide research: one compound engages GHRH receptors on pituitary somatotrophs, the other engages ghrelin receptors — parallel and independent pathways that preclinical data consistently shows produce a synergistic, supra-additive GH pulse.

// RESEARCH_PATHWAYS

This blend operates across two independent pituitary receptor axes — each producing GH release by a distinct mechanism, with preclinical evidence that the combination is greater than the sum of its parts:

• GHRH Receptor Axis (CJC-1295 no DAC): Binds GHRH receptors on anterior pituitary somatotrophs, elevates intracellular cAMP, activates Protein Kinase A, increases GH gene transcription and pulsatile secretion. Signal respects natural negative-feedback from somatostatin and circulating IGF-1.
• Ghrelin / GHSR-1a Axis (Ipamorelin): Binds ghrelin receptors on the pituitary and hypothalamus independently of the GHRH pathway, stimulating a separate GH secretion signal. Preclinical data also suggests GHRPs may transiently suppress somatostatin, potentiating the concurrent GHRH-axis response.
• Synergistic Dual Activation: When both pathways are engaged simultaneously, preclinical models report a supra-additive GH pulse — the amplitude and frequency of GH secretion exceed what either compound produces alone, producing a pattern more closely resembling endogenous pulsatile GH physiology than either agent in isolation.

// RESEARCH_AREAS

• GH axis secretion dynamics and pulsatility modeling
• Body composition investigations (lean mass / adipose ratios in animal models)
• IGF-1 upregulation and downstream anabolic signaling pathways
• Bone mineral density and osteoblast activity studies
• Tissue recovery and musculoskeletal repair in preclinical injury models
• Metabolic rate and substrate utilization research
• Sleep architecture and nocturnal GH pulse characterization

// COMMON_PROTOCOLS

In laboratory settings, the CJC-1295 no DAC / Ipamorelin combination is typically reconstituted in bacteriostatic water (BAC water). Researchers working with this blend administer both peptides in close temporal proximity — preclinical protocols often apply them simultaneously or within minutes of each other to capture the dual-receptor synergy window. Subcutaneous administration routes are most common in rodent models, frequently timed around fasting states or challenge protocols designed to isolate GH pulse dynamics. Studies investigating longer-term effects on body composition or bone density in animal models typically run extended observation windows of several weeks. Reconstituted peptide vials are stored refrigerated (2-8C); lyophilized product is stable at room temperature for shipping and short-term storage.

// THE_EVIDENCE_PICTURE

The CJC-1295 / Ipamorelin combination has a well-characterized mechanistic foundation and a growing body of preclinical support. The synergistic relationship between GHRH analogues and GHRPs is among the most replicated findings in in vitro and rodent GH-axis research — dual-receptor activation producing supra-additive GH release is a peer-reviewed, documented phenomenon across multiple study groups. Individual compound data includes published work on body composition outcomes, IGF-1 elevation, and bone turnover in animal models. Human clinical data for this specific combination remains limited; some pharmacokinetic work exists for CJC-1295 and Ipamorelin in isolation.

// DISCLAIMER

Research use only. Not FDA approved. Animal data dominant. Not for human consumption. Educational content only — anecdote does not equal evidence.